Tag Archives: innovative

Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

5 Jul

A venture capital firm that was founded in 2006 and is based in the Southern USA has managed $400 million in total assets, and recently closed its sixth fund. The firm typically makes equity investments into enterprise software, medical devices, and healthcare IT companies in the seed, series A, series B and series C stages. The typical investment size ranges from $3 million to $10+ million per company. The allocation numbers will vary over the next 6-9 months. For early-stage investments, the firm primarily invests in companies based in Texas, but they will also consider opportunities in the Southwest of the US.

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.

The firm generally seeks to invest in private companies. The firm will consider pre-revenue companies and has no specific requirements for the company’s management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA Venture Firm Seeks to Invest in Innovative Digital Health and Software-Based Diagnostic Companies

14 Jun

A venture capital firm with multiple offices in the USA is looking to invest in tech-driven companies that have at least one female on the leadership team. The firm invests in technology companies, including those in the healthcare sector, such as digital health and software-based diagnostics companies. The firm will invest primarily in series A-B rounds in USA-based companies with at least $1M in revenue. The firm will typically make initial investments between $1.5-5M.

The firm invests in technology companies in the digital health space that are solving some of the world’s greatest challenges. The firm particularly likes to see companies that are creating more affordable health solutions.

The firm does not require a board seat when investing, but may take one if the firm leads an investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Japanese Pharmaceutical with Established USA Subsidiary Seeks Innovative Early-Stage Therapeutics Assets in Neurodegenerative & Neurodevelopmental Diseases

14 Jun

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. The pharma also has a large USA-based subsidiary. Sponsored research may also be considered with a focus on Japan-based academic institutions.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS/neurology. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: